CLEARONE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CLEARONE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $46.07M | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $41.28M | Apr 2, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $41.80M | Apr 20, 2018 |
| FY2017 | Dec 31, 2016 | $48.64M | Apr 20, 2018 |
| FY2017 | Dec 31, 2015 | $57.80M | Apr 20, 2018 |
| FY2016 | Dec 31, 2014 | $57.91M | Mar 16, 2017 |
| FY2014 | Dec 31, 2013 | $49.59M | Jan 13, 2016 |
| FY2013 | Dec 31, 2012 | $46.42M | Mar 20, 2014 |
| FY2012 | Dec 31, 2011 | $46.07M | Mar 25, 2013 |
| FY2011 | Dec 31, 2010 | $41.28M | May 15, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($328.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($194.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.36M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.92M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $12.56M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.19M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.37M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $24.01M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $29.49M | Apr 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.98M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($560.0K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $20.56M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.69M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $505.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($8.41M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($16.69M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($14.17M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.44M | Apr 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.40M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.14M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.77M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($7.22M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.57M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($8.56M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.33M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($16.19M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.57M | Apr 20, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.30M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $4.39M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.51M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.78M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $7.84M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.34M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $8.58M | Apr 20, 2018 |
| FY2017 | Dec 31, 2015 | $8.32M | Apr 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($6.12M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $54.63M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.18M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.39M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($982.0K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.66M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($6.62M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($9.27M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.83M | Apr 20, 2018 |
| FY2017 | Dec 31, 2015 | $7.59M | Apr 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $196.0K | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $375.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $51.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $221.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $284.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $205.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $336.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $638.0K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $730.0K | Apr 20, 2018 |
| FY2017 | Dec 31, 2015 | $359.0K | Apr 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $50.69M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $83.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $66.19M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $62.32M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $55.11M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $58.92M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $67.88M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $88.12M | Apr 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.21M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.01M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.62M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.69M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $12.51M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $10.63M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.71M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.31M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $10.68M | Apr 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($714.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $21.33M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $44.69M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $74.13M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $51.50M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $49.81M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $44.48M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $52.20M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $56.57M | Apr 15, 2019 |
| FY2018 | Dec 31, 2016 | $77.45M | Apr 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 20, 2018 |
| FY2017 | Dec 31, 2016 | $12.72M | Apr 20, 2018 |
| FY2016 | Dec 31, 2015 | $12.72M | Mar 16, 2017 |
| FY2016 | Dec 31, 2014 | $12.72M | Mar 16, 2017 |
| FY2016 | Dec 31, 2013 | $3.47M | Mar 16, 2017 |
| FY2014 | Dec 31, 2012 | $3.47M | Jan 13, 2016 |
| FY2013 | Dec 31, 2011 | $1.15M | Mar 20, 2014 |
| FY2012 | Dec 31, 2010 | $726.0K | Mar 25, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.14M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.06M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.08M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($516.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($21.07M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($13.38M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($13.88M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.48M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.16M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $30.98M | Apr 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $17.84M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $984.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.07M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.80M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.06M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $11.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $5.57M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $12.10M | Apr 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.22M | Mar 30, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | (1) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | (1) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 1.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 23.96M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 23.96M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 22.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 18.78M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 16.65M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 16.63M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 8.32M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 8.81M | Apr 20, 2018 |